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a fragment of approximately 20KDa that it's not present in none of the 18
control samples analyzed. This fragment seems not to be speciﬁc of
MMP13 since it was present before the incubation with the protease, and
the intensity of the band did not increase with the in vitro MMP-13
digestion.
Conclusions: We found three ECM proteins susceptible of MMP13 diges-
tion that could be potential OA biomarkers. Interestingly, results showed
that 30% of OA patients had a MMP13 not speciﬁc fragment from OGN. The
presence or absence of this fragment could be useful as a tool to identify
a group of patients with similar characteristics
164
ANALYSIS OF THE SERUM BIOMARKERS IN HUMAN KNEE
OSTEOARTHRITIS
C. Daozhang, C. Yuxian, Z. Hua. The third afﬁliated Hosp. of Sun Yat-Sen
Univ., guangzhou, China
Purpose: Osteoarthritis (OA) is characterized by a degeneration of carti-
lage whose main clinical symptoms are pain, deformity and loss of func-
tion.With the coming of global aging society, OA has become a leading
cause of disability in the elderly.Its poorly understood pathogenesis limits
the discovery of targets for pharmacological intervention and there are few
effective medical treatments beyond pain control and surgery. Effective
method of early diagnosis and treatment of OA are desperately needed.
To search proteins that might serve as serum biomarkers for OA diagnosis,
treatment or pathogenesis, this study preformed technologies to identify
differentially expressed proteins from serum obtained from patients with
knee osteoarthritis(OA) and controls.
Methods: There are 4 subjects of OA and 4 age- and sex- matched normal
adults involved in the study, 4 subjects of OA are randomly selected from30
patients diagnosed with primary knee osteoarthritis. Serum samples from
each subject were treated with ProteoExtract Albumin/IgG Removal Kit
and Clean-up Kit, then cross-labeled with different CyDye, followed by two
dimension difference in gel electrophoresis(2D-DIGE), map scanning, and
then themaps of protein spots were compared using the software DeCyder
v6.0 to ﬁnd out the different expressed proteins. Treat these proteins with
Matrix assisted laser desorption ionization-time of ﬂight mass spec-
trometry(MALDI-TOF-MS), and get peptide ﬁnger printing maps(FPM),
then search themwithMASCOT in Swiss-Prot/Uniprot date base to identify
these proteins. Finally, use bioinformatics to analysis biological functions
and research value of these proteins.
Results: We found 14 differentially expressed protein spots compared
serum samples from patients with OA relative to the controls. The MS
revealed 14 proteins that alpha-2-macroglobulin, gelsolin, vitamin K-
dependent protein S, kininogen-1, complement C3 were increased, and
haptoglobin, inter-alpha-trypsin inhibitor heavy chain H4(ITIH4), apoli-
poprotein E were decreased in OA serum samples. Alpha-2-macroglobulin,
ITIH4, kininogen-1 were related to the body's inﬂammatory reaction,
vitamin K-dependent protein S, apolipoprotein E were involved in cell
apoptosis , and alpha-2-macroglobulin, complement C3 participated in
immune response. Some studies indicated that alpha-2-macroglobulin is
related to the degradation of cartilage extracellular matrix. Some studies
found that alpha-2-macroglobulin, apolipoprotein E, Complement 3, gel-
solin, haptoglobin and kininogen-1 appearanced in synovial [[Unsup-
ported Character - ﬂ]]uid, and apolipoprotein E, alpha- 2-macroglobulin,
haptoglobin increased in synovial [[Unsupported Character - ﬂ]]uid from
OA compared with the health controls.
Conclusions: 1,This study successfully settled the serum comparative
proteomics technique of OA, combined the 2D-DIGE and MALDI-TOF-MS,
which provided a valuable method for screening and identiﬁcation of
disease related proteins; 2,This study found that alpha-2-macroglobulin,
gelsolin, vitamin K-dependent protein S, kininogen-1, complement C3
were increased, and haptoglobin, inter-alpha-trypsin inhibitor heavy chain
H4(ITIH4), apolipoprotein E were decreased in OA serum samples. 3,The
result of bioinformatics analysis indicated that the pathogenesis of oste-
oarthritis might be related to inﬂammation, immune or cell apoptosis;
4,Alpha-2-macroglobulin,apolipoprotein E,complement C3,gelso-
lin,haptoglobin,kininogen-1 might be utilized as potential biomarkers fordiagnosis or treatment of OA, they also provided the new clues for the
future study of the OA pathogenesis.
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356-373 ELISA, A MORE SENSITIVE SANDWICH ASSAY FOR DETECTING
AGGRECAN FRAGMENTS CLEAVED BY ADATMSS AT 373-374 SITE, IS
A POTENTIAL BIOMARKER FOR HUMAN JOINT DISEASES.
B. Wang 1, A.-C.B. Jensen 1, K.T. Ngo 1, Y. Ding 2, P. Chen 1, M.A. Karsdal 1,
Q. Zheng 2, P. Qvist 1. 1Nordic BioSci., Copenhagen, DENMARK; 2Nordic
BioSci. Beijing, Beijing, China
Purpose: Aggrecan degradation is believed to be a crucial process in joint
diseases such as OA and RA. The ADAMTSs cleavage site TEGE373-
374ARGS is a hot spot for investigation of aggrecan degradation. We have
developed a competitive ELISA AGNx1 for detecting fragments containing
neo-epitope NITEGE373, and a sandwich ELISA G1-373 for detecting
fragment containing both NITEGE373 and an epitope located in G1/G2
domain of aggrecan. There are disadvantages for the existing ELISAs:
lower sensitivity for the fragment in serum samples and unsatisﬁed
technical performance result for G1-373 with higher coefﬁcient of vari-
ation (CV) variation.
The aim of this study was to develop a sandwich ELISA 356-373 with
higher sensitivity detecting fragments containing NITEGE373.The ELISAs
were characterized and compared by using the Full Depth Cartilage (FDC)
explant culture model.
Methods: Full depth bovine cartilage (FDC) including all subpopulations of
chondrocytes from superﬁcial zone to the deep zone of the cartilage
explants was obtained from the joint of one to two-year- old calf. The
pieces (20-25mg) were placed in 96-well plate and incubate for 21 days at
37C with 5% CO2. Serum freemedium containing oncostatin M and tumor
necrosis factor (TNF) alpha were replaced every second or third day and
store at -20C before analysis by: (1) competitive NITEGE373 ELISA
(AGNx1) detecting aggrecan fragments containing neo-epitope
NITEGE373, (2) sandwich G1-373 ELISA detecting aggrecan fragments
containing both neo-epitope NITEGE373 and G1 domain, (3) sandwich
356-373 ELISA detecting fragments containing both neo-epitope
NITEGE373 and epitope 352TVQTVTW358 in interglobular domain (IGD).
Results: We found that: (1) aggrecanase-derived aggrecan fragments
containing NITEGE373 were dose-dependently released in the early (day
2-7 of culturing) and mid phase (day 9-14) into the supernatant from FDC
explants stimulated with catabolic cytokines. (2) The fragments released,
proﬁled by the three assays, were similar but different: the NITEGE373
competitive ELISA and the 356-373 sandwich ELISA showed two peak
releases. The G1-373 sandwich ELISA only showed one release. (3) The
release of NITEGE373 fragments detected by NITEGE373 competitive ELISA
or the 356-373 sandwich ELISA was delayed by MMPs inhibitor GM6001,
whereas the fragments release detected with G1-373 sandwich ELISA was
partially but signiﬁcantly inhibited by GM6001 (33% inhibition), indicating
that MMPs are involved in G1-373 ELISA-detecting fragment derivation.
(4) Higher sensitivity and better technical performance data was achieved
for the 356-373 ELISA compared to NITEGE373 competitive ELISA and G1-
373 ELISA, respectively. (5) 356-373 ELISA could be applied for human
samples testing with good dilution recovery, indicating its further poten-
tial clinical application for joint diseases as a biomarker.
Conclusions: We developed a new sandwich ELISA detecting the
ADAMTSs derived fragments containing neo-epitope NITEGE373 and
another epitope 352TVQTVTW358 in IGD. This ELISA is more sensitive
than the previous competitive NITEGE373 ELISA which are lack of sensi-
tivity for human samples test, and more technically robust than the G1-
373 ELISA which has weak stability. Its clinical application, i.e., patient
samples detection, will be investigated in the coming future.
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